RT Journal Article
SR Electronic
T1 Evaluation of SARS-CoV-2 Antibody Point of Care Devices in the Laboratory and Clinical Setting
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.16.21267703
DO 10.1101/2021.12.16.21267703
A1 McCance, Kirsty
A1 Wise, Helen
A1 Simpson, Jennifer
A1 Bachelor, Becky
A1 Hale, Harriet
A1 McDonald, Lindsay
A1 Zorzoli, Azul
A1 Furrie, Elizabeth
A1 Chopra, Charu
A1 Muecksch, Frauke
A1 Hatziioannou, Theodora
A1 Bieniasz, Paul D.
A1 Templeton, Kate
A1 Jenks, Sara
YR 2021
UL http://medrxiv.org/content/early/2021/12/16/2021.12.16.21267703.abstract
AB SARS-CoV-2 Antibody tests have been marketed to diagnose previous SARS-CoV-2 infection and as a test of immune status. There is a lack of evidence on the performance and clinical utility of these tests. We aimed to carry out an evaluation of 14 point of care (POC) SARS-CoV-2 antibody tests.Serum from participants with previous RT-PCR (Real-Time Polymerase chain reaction) confirmed SARS-CoV-2 infection and pre-pandemic controls were used to determine specificity and sensitivity of each POC device. Changes in sensitivity with increasing time from infection were determined on a cohort of participants. Corresponding neutralising antibody status was measured to establish whether the detection of antibodies by the POC device correlated with immune status. Paired capillary and serum samples were collected to ascertain whether POC devices performed comparably on capillary samples.Sensitivity and specificity varied between the POC devices and in general did not meet the manufacturers reported performance characteristics signifying the importance of independent evaluation of these tests. The sensitivity peaked at >20 days following symptoms onset however sensitivity of 3 POC devices evaluated at extended time points showed that sensitivity declined with time and this was particularly marked at >140 days post infection onset. This is relevant if the tests are to be used for sero-prevelence studies. Neutralising antibody data showed positive antibody results on POC devices did not necessarily confer high neutralising antibody titres and these POC devices cannot be used to determine immune status to the SARS-CoV-2 virus. Comparison of paired serum and capillary results showed that there was a decline in sensitivity using capillary blood. This has implications in the utility of the test as they are designed to be used on capillary blood by the general population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLothian NRS BioResourceAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for access to pre-pandemic stored samples and hospitalised COVID-19 patient samples was obtained through the NRS BioResource (Ref: SR1410). Outpatient COVID-19 convalescent patient samples were obtained through the NRS BioResource (Ref: SR1407) and the COVID-19 Antibody Test Evaluation (CATE) study, with ethical approval from London-Brent Research Ethics Committee (REC ref: 20/HRA/3764 IRAS: 286538I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsLFA(lateral flow assay)POC(point of care)PPV(positive predictive value)NPV(negative predictive value)RT-PCR(real time polymerase chain reaction)NT50(half maximal neutralising titre)hCoV(Human Coronavirus)SARS-CoV-2(severe acute respiratory syndrome coronavirus 2)COVID-19(coronavirus disease 2019).